ProCE Banner Activity

The Evolving Treatment of AML and Higher-risk MDS: HMA Combinations


Download these slides from a live symposium for an expert review of the latest data on hypomethylating agent combination therapies for AML and higher-risk MDS.

Released: June 09, 2023



Michael Heuser

Michael Heuser, MD

Chair for Molecular Therapies in Hematology
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover Medical School
Hannover, Germany

Provided by

This activity is provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported by educational grant from Gilead Sciences, Inc. 

Gilead Sciences, Inc.